Atypical parkinsonism: An update

Current Opinion in Neurology

Volumn 26, Issue 4, 2013, Pages 401-405

  Stamelou, Maria ^a,b,c   Hoeglinger, Guenter U ^d,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF ATHENS   (Greece)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

atypical parkinsonian disorders; cerebrospinal fluid biomarkers; diagnostic; genetics; therapy

Indexed keywords

IMMUNOGLOBULIN; RASAGILINE;

CORTICOBASAL DEGENERATION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; PARKINSONISM; PATHOPHYSIOLOGY; PROCEDURES; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW;

DIAGNOSIS, DIFFERENTIAL; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NEUROIMAGING; PARKINSONIAN DISORDERS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 84880720963     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283632da6     Document Type: Review

References (36)

1. Stamelou M, Quinn N, Bhatia K. 'Atypical' parkinsonism: new genetic disorders presenting with features of PSP, MSA or CBD. Mov Disord 2013. [Epub ahead of print]
2. Hoglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011; 43:699-705.
3. Ahmed Z, Asi YT, Sailer A, et al. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 2012; 38:4-24.
4. The Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 2013. [Epub ahead of print]
5. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11:323-330.
6. Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 2012; 135:736-750.
7. Boeve BF, Boylan KB, Graff-Radford NR, et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 2012; 135:765-783.
8. Hodges J. Familial frontotemporal dementia and amyotrophic lateral sclerosis associated with the C9ORF72 hexanucleotide repeat. Brain 2012; 135:652-655.
9. O'Dowd S, Curtin D, Waite AJ, et al. C9ORF72 expansion in amyotrophic lateral sclerosis/frontotemporal dementia also causes parkinsonism. Mov Disord 2012; 27:1072-1074.
10. Lindquist S, Duno M, Batbayli M, et al. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clin Genet 2013; 83:279-283.
11. Lesage S, Le Ber I, Condroyer C, et al. C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain 2013; 136:385-391.
12. Le Ber I, Camuzat A, Guillot-Noel L, et al. C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. J Alzheimers Dis 2013; 34:485-499.
13. Rubio-Agusti I, Kojovic M, Edwards MJ, et al. Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review. Mov Disord 2012; 27:1769-1774.
14. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996; 60:615-620. (Pubitemid 26237111)
15. Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009; 132:156-171.
16. Respondek G, Roeber S, Kretzschmar H, et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and Neuroprotection and Natural History in Parkinson Plus Syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 2013; 28:504-509.
17. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80:496-503.
18. Stamelou M, Alonso-Canovas A, Bhatia KP. Dystonia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases. Mov Disord 2012; 27:696-702.
19. Stamelou M, Knake S, Oertel WH, Hoglinger GU. Magnetic resonance imaging in progressive supranuclear palsy. J Neurol 2011; 258:549-558.
20. Massey LA, Micallef C, Paviour DC, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord 2012; 27:1754-1762.
21. Hellwig S, Amtage F, Kreft A, et al. [18F]FDG-PET is superior to [123I]IBZMSPECT for the differential diagnosis of parkinsonism. Neurology 2012; 79:1314-1322.
22. Tripathi M, Dhawan V, Peng S, et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology 2013; 55:483-492.
23. Luk C, Compta Y, Magdalinou N, et al. Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three-and four-repeat tau isoforms in tauopathies. J Neurochem 2012; 123:396-405.
24. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011; 10:230-240.
25. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012; 69:1445-1452.
26. Tateno F, Sakakibara R, Kawai T, et al. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord 2012; 26:213-216.
27. Schoonenboom NS, Reesink FE, Verwey NA, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012; 78:47-54.
28. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011; 69:570-580.
29. Bech S, Hjermind LE, Salvesen L, et al. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord 2012; 18:69-72.
30. Constantinescu R, Mondello S. Cerebrospinal fluid biomarker candidates for parkinsonian disorders. Front Neurol 2012; 3:187.
31. Ishigami N, Tokuda T, Ikegawa M, et al. Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy. Mov Disord 2012; 27:851-857.
32. Poewe W, Barone P,Gliadi N, et al. A randomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the parkinsonian subtype. Mov Disord 2012; 27 (Suppl 1):1182.
33. Novak P, Williams A, Ravin P, et al. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol 2012; 12:131.
34. Lee PH, Lee JE, Kim HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012; 72:32-40.
35. Hoglinger GU, Huppertz HJ, Wagenpfeil FS, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial; Alzheimer's Association International Conference; 2012, Vancouver, British Columbia, Canada, Proposal number: 34102.
36. Stamelou M, de Silva R, Arias-Carrion O, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain 2010; 133:1578-1590.